

## PRESS RELEASE

### **THE CADISS® DEVICE AVAILABLE FOR MUSCULOSKELETAL AND EAR SURGERY IN UNITED KINGDOM AND REPUBLIC OF IRELAND**

**Louvain-la-Neuve – May 2022** – AuXin Surgery is participating to the Belgian Economic Mission to the United Kingdom - 9-12 may 2022. The company is launching officially its surgical device named the “**CADISS® System**” in the UK and in the Republic of Ireland.

**AuXin Surgery** offers a safe, fast-learning and clinically validated system, **the CADISS® System**, that empowers healthcare providers to improve radically the outcome of surgery while preserving their surgical techniques.

**What?** A unique method: a novel line of medical devices for the selective dissection of pathological tissues and fibrosis. The system is able to facilitate many surgical procedures while preserving critical organs such as nerves, muscles or blood vessels. A pharmaceutical molecule instilled in the surgical field rapidly reduces adhesion between tissues, and combined with non-cutting dissectors, facilitates their atraumatic detachment. Pathological tissues are separated from healthy tissues much more easily and safely than with other techniques, resulting in less damages to healthy organs and less relapses.

**For whom?** CADISS® system can be used in several separate surgery with the benefit to preserve surrounding healthy structures. CADISS® is currently approved for ear surgeries and musculoskeletal surgeries.

**Why?** CADISS® meets a real need for the surgeons, the patients and the healthcare system by providing an easier and safer solution. Surgeons do not have to change their way of dissecting; they just have to add CADISS® to it.

As a result, thousands of patients will have the opportunity to benefit from CADISS®: less side-effects and less relapse risks, with a better preservation of patient’s body and healthy tissues. For example, CADISS® has been demonstrated to reduce damages to spinal cord by ~70% in case of revision surgery.

**CADISS® in UK & Republic of Ireland** : The CADISS® system is now available in the UK and the Republic of Ireland based on the new exclusive collaboration with **Severn Healthcare**.

This contract signature is the beginning of a very strong partnership within a very competitive market. **Severn Healthcare & AuXin Surgery** have the complementarity and capabilities to help each other growing on long term.

*“Severn Healthcare are a leading supplier of specialist products in ENT, Neurosurgery, Plastics and Otolaryngology with many years of accumulated experience in these markets. We are delighted to have entered into a partnership with Auxin Surgery, manufacturers of a unique and novel technology called CADISS® which improves surgical outcomes through the safe and effective dissection of soft tissues. CADISS® is a perfect fit for Severn as it has applications across many of these specialties. Our close collaboration means that we are now able to offer this exciting technology to surgeons in the UK and Republic of Ireland”*

**Sacha Bartlett, Managing Director – Severn Healthcare Ltd.**

**Contact person :**

**Xavier DELCORPS** | Chief Commercial Officer : + 32 470 85 50 61 | [x.delcorps@auxin.eu](mailto:x.delcorps@auxin.eu)

**EXECUTIVE SUMMARY :**

*AuXin Surgery is the pioneer of chemically assisted surgical dissection. The company was established in January 2014, and has since developed its medical devices named the CADISS® system. This technology makes delicate operations safer to the benefits of both surgeons and patients. This innovative method is now available to surgeons in their day-to-day practice. The Company develops and sells the complete CADISS® system, which is CE Class III granted since January 2019 for the first targeted surgical applications (musculoskeletal surgery and ear surgery). This system is the first commercially available chemically assisted surgical dissection system, and is on the way to be granted for new surgical indications. The company ambitions to distribute worldwide its surgical innovation: the CADISS® system is currently actively commercialized in 19 countries, in Europe and abroad, and totalizes 32 countries under distribution contract (statement of April 2022). This important internationalization process is realized in close relationship with the AWEX, the Walloon region Export Agency.*